Literature DB >> 26193055

Erdosteine protects HEI-OC1 auditory cells from cisplatin toxicity through suppression of inflammatory cytokines and induction of Nrf2 target proteins.

Se-Jin Kim1, Channy Park2, Joon No Lee1, Hyewon Lim3, Gi-Yeon Hong3, Sung K Moon2, David J Lim2, Seong-Kyu Choe4, Raekil Park5.   

Abstract

Cisplatin has many adverse effects, which are a major limitation to its use, including ototoxicity, neurotoxicity, and nephrotoxicity. This study aims to elucidate the protective mechanisms of erdosteine against cisplatin in HEI-OC1 cells. Pretreatment with erdosteine protects HEI-OC1 cells from cisplatin-medicated apoptosis, which is characterized by increase in nuclear fragmentation, DNA laddering, sub-G0/G1 phase, H2AX phosphorylation, PARP cleavage, and caspase-3 activity. Erdosteine significantly suppressed the production of reactive nitrogen/oxygen species and pro-inflammatory cytokines such as tumor necrosis factor-α, interleukin (IL)-1β, and IL-6 in cisplatin-treated cells. Studies using pharmacologic inhibitors demonstrated that phosphatidylinositol-3-kinases (PI3K) and protein kinase B (Akt) have protective roles in the action of erdosteine against cisplatin in HEI-OC1 cells. In addition, pretreatment with erdosteine clearly suppressed the phosphorylation of p53 (Ser15) and expression of p53-upregulated modulator of apoptosis. Erdosteine markedly induces expression of NF-E2-related factor 2 (Nrf2), which may contribute to the increase in expression of glutathione redox genes γ-l-glutamate-l-cysteine-ligase catalytic and γ-l-glutamate-l-cysteine-ligase modifier subunits, as well as in the antioxidant genes HO-1 and SOD2 in cisplatin-treated HEI-OC1 cells. Furthermore, the increase in expression of phosphorylated p53 induced by cisplatin is markedly attenuated by pretreatment with erdosteine in the mitochondrial fraction. This increased expression may inhibit the cytosolic expression of the apoptosis-inducing factor, cytochrome c, and Bax/Bcl-xL ratio. Thus, our results suggest that treatment with erdosteine is significantly attenuated cisplatin-induced damage through the activation of Nrf2-dependent antioxidant genes, inhibition of pro-inflammatory cytokines, activation of the PI3K/Akt signaling, and mitochondrial-related inhibition of pro-apoptotic protein expression in HEI-OC1 auditory cells.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26193055     DOI: 10.1016/j.taap.2015.07.014

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  6 in total

1.  The impact of erdosteine on cisplatin-induced ototoxicity: a proteomics approach.

Authors:  Sofia Waissbluth; Delphine Garnier; Olubunmi V Akinpelu; Pezhman Salehi; Sam J Daniel
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-11-23       Impact factor: 2.503

2.  Amelioration of Cisplatin-Induced Ototoxicity in Rats by L-arginine: The Role of Nitric Oxide, Transforming Growth Factor Beta 1 and Nrf2/HO-1 Pathway.

Authors:  Remon S Estfanous; Walaa S Elseady; Ahmed M Kabel; Rasha A Abd Ellatif
Journal:  Asian Pac J Cancer Prev       Date:  2020-07-01

3.  Cannabidiol Promotes Endothelial Cell Survival by Heme Oxygenase-1-Mediated Autophagy.

Authors:  Sabine Böckmann; Burkhard Hinz
Journal:  Cells       Date:  2020-07-16       Impact factor: 6.600

4.  Loss of STAT1 protects hair cells from ototoxicity through modulation of STAT3, c-Jun, Akt, and autophagy factors.

Authors:  S Levano; D Bodmer
Journal:  Cell Death Dis       Date:  2015-12-17       Impact factor: 8.469

5.  NLRX1 accelerates cisplatin-induced ototoxity in HEI-OC1 cells via promoting generation of ROS and activation of JNK signaling pathway.

Authors:  Haiyan Yin; Gaoying Sun; Qianqian Yang; Chen Chen; Qi Qi; Haibo Wang; Jianfeng Li
Journal:  Sci Rep       Date:  2017-03-13       Impact factor: 4.379

6.  Tissue-Protective Effect of Erdosteine on Multiple-Organ Injuries Induced by Fine Particulate Matter.

Authors:  Lei Cao; Fen Ping; Fengrui Zhang; Haixiang Gao; Ping Li; Xiaohui Ning; Guohuan Cui; Zheng Ma; Xin Jiang; Suyan Li; Shuzhi Han
Journal:  Med Sci Monit       Date:  2021-12-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.